CardioVascular Dynamics merges with Radiance Medical Systems:
This article was originally published in Clinica
CardioVascular Dynamics has signed a definitive merger agreement to acquire all outstanding shares of Radiance Medical Systems, a developer of catheter-based radiation treatments. CardioVascular will pay around $7 million in shares. Depending on development milestones being achieved, around $6.9 million of additional CardioVascular shares will be issued to Radiance shareholders. Last month, CardioVascular bought 1.5 million shares in Radiance to give it 50% of the company (see Clinica No 830, p 11).
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.